SAN FRANCISCO--(BUSINESS WIRE)--Savonix, the company revolutionizing access to brain data, launches today the open beta of the world’s first fully mobile, clinically valid digital neuro-cognitive assessment, Savonix Mobile. The state-of-the-art cognitive and emotional function evaluation provides an accurate, accessible, actionable and affordable tool for professional cognitive screening. Led by former Stanford Medical healthcare professionals, and built using the published data from decades of clinical trials research in cognitive assessment, Savonix is the only mobile evidence-based, digital cognitive assessment on the market.
Following a two month closed beta with select industry leaders, Savonix is opening the fully-functioning application to consumers for a six week open beta to receive user feedback. Users download the application for free in the Apple App Store or Google Play, register for a login and access key on the Savonix website, and proceed to complete the assessment and receive their results via the mobile application. Following the close of the open beta, Savonix will remain in the app stores available exclusively to end users via Savonix licenses with healthcare organizations.
Until Savonix, cognitive assessment remained locked inside dated, analogue processes that are costly, time consuming and only accessible through a clinician. The test, which is used for screening cognitive and emotional function, is accessible via any iOS or Android device during the open beta. Users can take the set of clinically valid neuro-cognitive tests to receive results in multiple domains, such as:
- Verbal memory
- Impulse control
- Sustained attention
- Information processing speed
- Cognitive flexibility
- Emotionality
- Working memory
- Executive function
- Emotion regulation
- Decision making
Suitable for children, adults and older adults, the assessment takes an average of 30 minutes to complete. For companies and clinicians using the tool, Savonix provides full individual and group level reports, analysis and data to improve patient outcomes in a variety of health problems. During the limited time open beta, independent users receive their results in the mobile application, which they can present to a clinician for additional evaluation and diagnoses.
“We are unleashing the power of neurocognitive assessment by making it affordable and widely accessible, in the palm your hand,” says Savonix founder Mylea Charvat, Ph.D. “The platform has already demonstrated great value to beta users by providing a quick and accurate evaluation of neuro-cognitive function.”
The primary focus of the open beta program will be soliciting feedback on user experience. To date, key upgrades from the closed beta include:
- Superior images to increase task comprehension
- Improved error messaging for incorrect data inputs
- In-app notifications when the user is out of network or Wi-Fi range
- Countdown bar for percent complete
- Improved responsiveness to tap and point-and-drag functionality
- User interface improvements including colors, button messages and timing of screen transitions
Visit the App Store or Google Play to download the application.
About Savonix
Savonix is neuroscience democratized. Its digital, research-based assessment delivers a state-of-the-art cognitive and emotional function evaluation. The evidence-based screening is a 30-minute (on average) assessment accessed from any iOS or Android device. Savonix Mobile is an accurate, accessible, actionable and affordable tool for professional cognitive screening. Savonix raised $1.5 million in seed round funding, led by RoundGlass Partners, with Kickstart Seed Fund, BMNT capital and angel investors Bandel Carano and Ed Glassmeyere in October 2015.
Dr. Mylea Charvat is a translational neuroscientist, entrepreneur, and the CEO and founder of Savonix. She completed her Ph.D. Fellowship in Clinical Neuroscience at Stanford School of Medicine after receiving her Ph.D. in clinical psychology from Palo Alto University. Empowered by her passion to make access to cognitive screens easy and affordable, Mylea transitioned out of her clinical and academic role to begin the development of Savonix in 2014.
To learn more about Savonix and the mobile assessment, visit www.Savonix.com.
